HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
3-α-Hydroxy-7-oxo-5-β-cholan-24-sure
7-KETOLITHOCHOLIC ACID · Nutriacholic acid · 3α-Hydroxy-7-oxo-5β-cholan-24-oic acid · 7-Oxolithocholic acid · 7-KLA · 3α-Hydroxy-7-ketocholanic acid · 3a-Hydroxy-7-oxo-5b-cholanic acid · Chenodeoxycholic acid EP Impurity F
Identifikatoren & physikalische Daten
| CAS No. | 4651-67-6 |
|---|---|
| Summenformel | C24H38O4 |
| Durchschnittliche Molmasse | 390,6 g/mol |
| Monoisotopische Masse | 390,27700969 g/mol |
| SMILES | C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
| InChIKey | DXOCDBGWDZAYRQ-AURDAFMXSA-N |
| PubChem CID | 444262 |
| ChEMBL | CHEMBL1254169 |
| ChEBI | CHEBI:82679 |
| EC No. | 225-083-2 |
| DTXSID | DTXSID501032263 |
| Lokaler Name | 3-α-Hydroxy-7-oxo-5-β-cholan-24-sure |
Chemische & physikalische Eigenschaften
| XLogP | 4,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 74,6 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 4 |
| Schwere Atome | 28 |
| Formalladung | 0 |
| Komplexität | 645 |
| Collision Cross Section | 200.3 Ų [M-H]- [CCS Type: DTBuffer gas: N2Ionization: ESI-Dataset: Bile Acids]201.3 Ų [M+Na]+ [CCS Type: DTIonization: ESI+201.2 Ų [M+Na]+ [CCS Type: DT199.0 Ų [M+H]+ [CCS Type: DT189.0 Ų [M+H]+ [CCS Type: DT |
| Schmelzpunkt | 205°C |
| Siedepunkt | 545.9±25.0 °C(Predicted) |
| Dichte | 1.124±0.06 g/cm3(Predicted) |
| Lagerbedingungen | Sealed in dry,Room Temperature |
| Löslichkeit | Dioxane (Slightly), DMSO (Slightly), Methanol (Slightly)2.062mg/L at 25℃ |
| pKa (Säurekonstante) | 4.76±0.10(Predicted) |
| Aggregatzustand | Solid |
| Farbe | White to Off-White |
| InChIKey | DXOCDBGWDZAYRQ-QHVQYUNXNA-N |
| SMILES | C(O)(=O)CC[C@H]([C@@H]1[C@@]2(C)CC[C@]3([H])[C@@]4(C)CC[C@@H](O)C[C@@]4([H])CC(=O)[C@@]3([H])[C@]2([H])CC1)C |&1:5,6,7,11,13,17,20,25,27,r| |
| LogP (Verteilungskoeffizient) | 3.48 at 20℃ |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 27.3% (3 of 11) of reports.WarningH302 (18.2%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (54.5%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (54.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 11 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 3 of 11 reports by companies.There are 4 notifications provided by 8 of 11 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Regulatorische Informationen | Status: Active Update: 10-10-2014 https://echa.europa.eu/registration-dossier/-/registered-dossier/5428Status: Active Update: 28-11-2017 https://echa.europa.eu/registration-dossier/-/registered-dossier/21228 |
| Hazard Classes and Categories | Acute Tox. 4 (18.2%)Skin Irrit. 2 (54.5%)Eye Irrit. 2 (54.5%) |
| Wassergefährdungsklasse (WGK) | WGK 3 |
| Sicherheitshinweise (S) | 22-24/25 |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Verwenden
Nutriacholic Acid (Ursodeoxycholic Acid EP Impurity F) is derivative of Lithocholic Acid (L469180), a cholic acid derivative as TGR5 modulator.
Verwenden
3alpha-Hydroxy-7-oxo-5beta-cholanic Acid is an intermediate in organic synthesis and pharmaceutical research and development. It can be used to synthesize the choleretic drug Obeticholic acid. Obeticholic acid can inhibit cholic acid synthesis. It is commonly used to treat primary biliary cirrhosis and nonalcoholic fatty liver disease.